SONOMINDTM is a medical device company dedicated to tackling drug-resistant depression and other neurological and psychiatric disorders using its groundbreaking ultrasound-based, non-invasive
neuromodulation technology. Sonomind’s breakthrough innovation precisely targets the deep brain regions involved in depression in a non-invasive and entirely safe manner. This solution offers a new hope for the tens of millions in Europe – and 300 millions worldwide – who live with drug-resistant depression, paving the way for effective treatments without side effects.